|
業務類別
|
Biotechnology |
|
業務概覽
|
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli. |
| 公司地址
| 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404 |
| 電話號碼
| +1 650 667-4085 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.mirumpharma.com |
| 員工數量
| 372 |
| Dr. Joanne Quan, M.D. |
Chief Medical Officer |
美元 520.00K |
23/04/2026 |
| Mr. Jody Howe |
Senior Vice President, Global Controller and Principal Accounting Officer |
-- |
25/02/2026 |
| Mr. Christopher Peetz |
Director and Chief Executive Officer |
美元 755.00K |
23/04/2026 |
| Mr. Peter Radovich |
Chief Operating Officer and President |
美元 572.50K |
23/04/2026 |
| Mr. Eric H. Bjerkholt, M.B.A. |
Chief Financial Officer |
美元 520.00K |
23/04/2026 |
|
|
| Ms. Laura A. Brege |
Independent Director |
23/04/2026 |
| Mr. Timothy P. Walbert |
Independent Director |
23/04/2026 |
| Mr. Patrick J. Heron |
Independent Director |
23/04/2026 |
| Dr. Laurent Fischer, M.D. |
Independent Director |
23/04/2026 |
| Mr. Christopher Peetz |
Director and Chief Executive Officer |
23/04/2026 |
| Mr. William Carl Fairey, Jr |
Independent Director |
23/04/2026 |
| Mr. Michael Grey |
Chairman of the Board |
23/04/2026 |
| Ms. Sona Saira Ramasastry, M.Phil,M.S. |
Independent Director |
23/04/2026 |
| Dr. Lon Cardon, PhD |
Independent Director |
23/04/2026 |
|
|
|
|
